The most recent revelations from an international phase 3 clinical trial showcase that those who commenced the antiviral drug ensitrelvir within 72 hours after a family member tested positive for COVID-19 had substantially decreased likelihood of infection. Shionogi, a Japanese pharmaceutical conglomerate, created ensitrelvir, which is currently permitted in Japan for handling mild to moderate…